Hepatitis C is not a 'silent disease'

Benefits of new combination therapy are not just long-term

The benefits of treating hepatitis C are not just the prevention of potential serious liver complications, but are more immediate in terms of the quality of life of patients. "Hepatitis C is not a silent disease," says Dr. John E. Ware, Jr. of Quality Metric, Inc. in Lincoln, Rhode Island. "The disease limits patients substantially in terms of what they are able to do and how they feel," says Ware. Successful treatment improves quality of life and is likely to lead to a reduced need for health care services and increased productivity at work, according to Ware.

The results of the first international study of quality of life outcomes in hepatitis C conducted by the International Hepatitis Interventional Therapy Group are reported by Ware and his colleagues in the August issue of HEPATOLOGY, the monthly peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).

"This study is the first to link the clinical success of new combination therapies for hepatitis C to how much patients are helped in their everyday lives. Those who were treated successfully according to clinical tests were also the only ones who improved in terms of their quality of life as measured by energy level, social functioning with friends and relatives, and reductions in their level of distress," Ware says.

Over 300 patients in ten countries participated in this international study, using a self-administered Hepatitis Quality of Life Questionnaire that is available from QualityMetric, Inc. (www.qmetric.com ). By translating the quality of life questionnaires into other languages, results observed in the United States and the United Kingdom for English-speaking patients could be compared with results in other countries. Comparisons revealed a similar pattern of results, although similarit

Contact: Kirk Monroe
American Association For The Study of Liver Diseases

Page: 1 2

Related biology news :

1. Risk of Hepatitis E from consumption of deer?
2. Hepatitis C infection does not alter HIV progression or treatment
3. Need, potential for Hepatitis C vaccine highlighted by Hopkins study
4. Hepatitis E recovered from rats in Los Angeles
5. Hepatitis C drug overwhelms virus with flood of mutations - surprising mechanism may improve anti-viral treatments, UCSF study finds
6. Explaining the persistence of Hepatitis C
7. High percentage of Hepatitis C patients take herbs and vitamins, according to Rush survey
8. Jefferson scientists show drug is effective against a Hepatitis C Virus model in the laboratory
9. Hepatitis E virus infection may be widespread in rats
10. Hepatitis Cs interferon resistance mechanism discovered
11. Immune Response To Hepatitis B Spares Liver Cells

Post Your Comments:

(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
Breaking Biology Technology:
Cached News: